Otsuka reported that Voyxact (a CAM/capsid-modulating strategy is not implied here; the article describes kidney-function effects) slowed the loss of kidney function in IgA nephropathy, but the benefit was less than expected. In the Phase 3 study, patients receiving Voyxact had an annualized eGFR decline of 3 points over one year versus 7.6 points with placebo. The company framed the result as a clinical improvement, while the reporting noted there was still room for competing therapies to show greater effect. The primary focus remains on whether the magnitude of kidney-function preservation is sufficient for future regulatory and market positioning. The late-stage readout raises the bar for next entrants in IgA nephropathy as the field continues to differentiate treatments on both efficacy magnitude and safety across patient subgroups.